Table 3.

HRs and 95% CI for cause-specific mortality and clinicopathologic and the KRAS-LCS6 variant in 734 CRC cases from the Netherlands Cohort Study on diet and cancer

		Early stage (stage I and II) CRC	Stage III CRC	Stage IV CRC
KRAS-LCS6 variant		0.46 (0.18–1.14)	0.98 (0.55–1.74)	0.42 (0.17–1.06)
KRAS-LCS6 variant without KRAS mutations		0.77 (0.30–1.97)	0.95 (0.44–2.05)	0.35 (0.11–1.13)
KRAS-LCS6 variant with KRAS mutations		No CRC-related deaths	1.52 (0.66–3.54)	0.60 (0.19–1.91)
Sex (male)		0.97 (0.60–1.57)	0.92 (0.59–1.45)	0.85 (0.44–1.64)
Age at diagnosis		0.99 (0.94–1.05)	1.01 (0.96–1.06)	1.02 (0.93–1.10)
Grade	1	1 (reference)	1 (reference)	1 (reference)
	2	1.40 (0.51–5.70)	0.91 (0.34–2.45)	2.14 (0.28–16.38)
	3	0.77 (0.09–6.72)	1.90 (0.52–6.94)	14.47 (1.25–167.07)
	4	–	4.17 (0.72–24.05)	62.36 (2.11–1837.24)
Sublocation of the tumor	Proximal	1 (reference)	1 (reference)	1 (reference)
	Distal	0.76 (0.41–1.43)	0.67 (0.37–1.19)	0.55 (0.24–1.24)
	Rectosigmoid	0.32 (0.11–0.94)	0.60 (0.24–1.48)	0.95 (0.27–3.35)
	Rectum	0.49 (0.18–1.36)	0.24 (0.08–0.69)	0.35 (0.06–1.87)